Share on StockTwits

Exelixis (NASDAQ:EXEL) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the stock, Analyst RN reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.70.

A number of analysts have recently weighed in on EXEL shares. Analysts at Piper Jaffray downgraded shares of Exelixis from an “overweight” rating to a “neutral” rating in a research note on Tuesday. Analysts at Cowen and Company downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating in a research note on Tuesday.

Shares of Exelixis (NASDAQ:EXEL) traded down 53.14% during mid-day trading on Tuesday, hitting $1.94. The stock had a trading volume of 21,404,320 shares. Exelixis has a 1-year low of $3.02 and a 1-year high of $8.41. The stock has a 50-day moving average of $4.03 and a 200-day moving average of $4.33. The company’s market cap is $378.5 million. Exelixis also saw a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 48,189,006 shares, a decline of 4.7% from the July 31st total of 50,541,127 shares. Based on an average trading volume of 2,285,198 shares, the short-interest ratio is presently 21.1 days. Approximately 25.5% of the shares of the stock are sold short.

Exelixis (NASDAQ:EXEL) last released its earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.01. The company had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.66 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. The company’s revenue for the quarter was down 44.7% on a year-over-year basis. Analysts expect that Exelixis will post $-1.54 EPS for the current fiscal year.

Exelixis, Inc (NASDAQ:EXEL) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.